Failure of terfenadine in relieving the pruritus of atopic dermatitis.
We report the results of a double-blind, placebo-controlled, cross-over study of terfenadine 120 mg twice daily for pruritus in atopic dermatitis. Twenty-eight subjects with chronic atopic dermatitis received both terfenadine 120 mg b.d. and placebo each for a period of 1 week. Response was recorded by the subjects using visual analogue scales for severity of pruritus twice daily for the last 4 days of each treatment phase. There was no benefit from terfenadine.
Berth-Jones
J
J
Department of Dermatology, Leicester Royal Infirmary, U.K.
Graham-Brown
R A
RA
D000293:Adolescent; D000328:Adult; D000368:Aged; D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D002648:Child; D003876:Dermatitis, Atopic / Q000150:complications*; D004311:Double-Blind Method; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D011537:Pruritus / Q000188:drug therapy* / Q000209:etiology; D016032:Randomized Controlled Trials as Topic; D016593:Terfenadine
D001559:Benzhydryl Compounds; D006634:Histamine H1 Antagonists; D016593:Terfenadine